SciSparc Ltd., a specialty clinical-stage pharmaceutical company, has announced the commencement of patient recruitment for its clinical trial of SCI-210 in children with Autism Spectrum Disorder (ASD). The trial is set to take place at Soroka Medical Center in Israel, with the aim of enrolling 60 subjects aged between five and 18 over a 20-week period. The study is a double-blind, randomized, and placebo-controlled trial designed to evaluate the efficacy of SCI-210—a combination of cannabidiol (CBD) and CannAmide™—compared to standard CBD treatment in managing ASD symptoms. The company's CEO, Oz Adler, expressed optimism about the trial's potential to meet an unmet medical need and the company's goal to commercialize SCI-210 in Israel, followed by...Show More

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, has announced the commencement of patient recruitment for its clinical trial of SCI-210 in children with Autism Spectrum Disorder (ASD). The trial is set to take place at Soroka Medical Center in Israel, with the aim of enrolling 60 subjects aged between five and 18 over a 20-week period. The study is a double-blind, randomized, and placebo-controlled trial designed to evaluate the efficacy of SCI-210—a combination of cannabidiol (CBD) and CannAmide™—compared to standard CBD treatment in managing ASD symptoms. The company's CEO, Oz Adler, expressed optimism about the trial's potential to meet an unmet medical need and the company's goal to commercialize SCI-210 in Israel, followed by other markets pending regulatory approval. The trial will measure efficacy using the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire, the Clinical Global Impressions-Improvement (CGI-I) scale, and the determination of an effective therapeutic dose. SciSparc has consulted with the National Autism Research Center in Israel for the trial's design. The announcement was made on January 29, 2024, and is part of SciSparc's broader focus on developing cannabinoid-based pharmaceuticals for central nervous system disorders.